Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525558 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL524835 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL28036073 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL3426738 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL524545 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL3976225 | 0.99 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL97613 | 0.96 | KMT2A (0.50) | KMT2AFABP5FABP7TLR2CA1 | |
| Succinic Acid SCHEMBL28760118 | 0.95 | KMT2A (0.50) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL28463133 | 0.91 | KMT2A (0.48) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL14947096 | 0.91 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912519-A | Double-target targeted polypeptide compound, preparation method and application | 中国人民解放军总医院第一医学中心 | 2025-05-02 | — | — | CN | claimed |
| EP-4735047-A1 | PEGYLATED LINKERS AND USES THEREOF | Université de Tours (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731229-A1 | SIRNA, CONJUGATE WHICH CONTAIN SIRNA, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hansoh Bio LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4729529-A1 | PREPARATION OF PEPTIDE INHIBITOR OF INTERLEUKIN-23 RECEPTOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| US-12516145-B2 | Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization | NORTHWESTERN UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-5726243-A | Mild solid-phase synthesis of aligned, branched triple-helical peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0785941-A1 | PORPHYRIN LABELING OF POLYNUCLEOTIDES | STRATAGENE (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997017984-A1 | OLIGODENDROCYTE-SPECIFIC PROTEIN AND METHOD FOR TREATING DISEASE | RESEARCH GENETICS, INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5591646-A | Method and apparatus for peptide synthesis and screening | ARRIS PHARMACEUTICAL (US) | 1997-01-07 | — | — | US | disclosed |
| US-5585275-A | Pilot apparatus for peptide synthesis and screening | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-12-17 | — | — | US | disclosed |
| US-5576419-A | Mild solid-phase synthesis of aligned branched triple-helical peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996011937-A1 | PORPHYRIN LABELING OF POLYNUCLEOTIDES | STRATAGENE (US) | 1996-04-25 | — | — | WO | disclosed |
| WO-1994005394-A1 | SPECIFICATION METHOD AND APPARATUS FOR PEPTIDE SYNTHESIS AND SCREENING | ARRIS PHARMACEUTICAL CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0541663-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002542-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS HAVING GLYCOPROTEIN HORMONE AGONISTIC OR ANTAGONISTIC ACTIVITY | STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT (NL) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | FN1, INHA, EDNRB | KMT2A 1886/4885FABP5 814/4885FABP7 343/4885 |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | KMT2A 3210/4885FABP5 223/4885FABP7 369/4885 |
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, APOB, APOL1 | KMT2A 3305/4885FABP5 748/4885FABP7 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.